Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
Authors not yet confirmed · 2023 · Primary source linked above
What does this source report?
The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.
- Population and setting
- Patent chemistry and preclinical examples
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- See source; English abstract or translated patent text where available
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Patent claims are not evidence of approved clinical uses.
- Reconcile shared experiments and corrected publication records.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected original-source text checked; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Author unconfirmed. Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9 Primary source linked above 2023.
Molekul research summary: https://molekul.io/research/rp-nt3-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry